Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches

Cancer immunotherapy has evolved dramatically with improved understanding of immune microenvironment and immunosurveillance. The immunogenicity of breast cancer is rather heterogeneous. Specific subtypes of breast cancer such as estrogen receptor (ER)-negative, human EGF receptor 2 (HER2)-positive,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoub, Nehad M, Al-Shami, Kamal M, Yaghan, Rami J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340364/
https://www.ncbi.nlm.nih.gov/pubmed/30697064
http://dx.doi.org/10.2147/BCTT.S175360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340364/
https://www.ncbi.nlm.nih.gov/pubmed/30697064
http://dx.doi.org/10.2147/BCTT.S175360

Ejemplares similares